SC
AEON icon

Sculptor Capital’s AEON Biopharma AEON Stock Holding History

Sculptor Capital’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,656
Closed -$4.82M – 551
2022
Q4 		$4.82M Hold
6,656
– – 0.08% 261
2022
Q3 		$4.72M Hold
6,656
– – 0.06% 383
2022
Q2 		$4.7M Hold
6,656
– – 0.05% 426
2022
Q1 		$4.69M Buy
+6,656
New +$4.67M 0.04% 458
2021
Q4 		– Sell
-2,083
Closed -$1.46M – 1133
2021
Q3 		$1.46M Hold
2,083
– – 0.01% 530
2021
Q2 		$1.45M Buy
+2,083
New +$1.46M 0.01% 557

Other funds holding AEON

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
GCWM
Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

Sculptor Capital's AEON Position: Q1 2023 in Review

Sculptor Capital sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 6,656 shares — an estimated $4.82M sold.

Sculptor Capital first reported a position in AEON in Q2 2021 and held it in 6 quarters. The position peaked at $4.82M in Q4 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

  • Sculptor Capital reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
  • Sculptor Capital sold 6,656 AEON Biopharma shares in Q1 2023, an estimated $4.82M.
  • Sculptor Capital first reported a position in AEON Biopharma in Q2 2021 and held it in 6 quarters.
  • Sculptor Capital's AEON Biopharma position peaked at $4.82M in Q4 2022.
  • 21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on Sculptor Capital's 13F filing for Q1 2023, filed 16 May 2023.